ConjuChem
CompanyCanada
ConjuChem develops one asset, in phase 2 (CJC-1134-PC in type 2 diabetes). Mostly peptide acting on Insulin/IGF-1 signalling and GLP1R; based in Canada.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1Long-acting exendin-4 albumin conjugate that activates the glucagon-like peptide-1 receptor
Phase 2, Peptide, Insulin/IGF-1 signalling, GLP1R, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Similar companies6